Johnson & Johnson (NYSE:JNJ) Stock Jumps 2% – What’s Next?

Posted by Geri Gentry on Nov 9th, 2026

Shares of Johnson & Johnson (NYSE:JNJ – Get Free Report) traded up 2% during trading on Monday. The stock traded as high as $282.73 and last traded at $281.8640. Approximately 6,897,281 shares traded hands during trading, a decline of 13% from the average daily volume of 7,970,804 shares. The stock had previously closed at $276.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Investigational drug ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive adults with psoriatic arthritis, adding a late-stage potential growth opportunity to J&J’s immunology pipeline. Article: Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies
Positive Sentiment: A first-in-human Phase 1 study of pasritamig plus JNJ-9401 reported PSA reductions of at least 50% in 11 of 15 patients at the recommended regimen; nearly half had reductions of at least 90%. The early signal and reported safety profile are encouraging, and J&J plans to advance the combination to Phase 3. Article: Johnson & Johnson reports 73% PSA response rate
Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease, including findings on symptom improvements patients value. Alongside the ICOTYDE results, the updates showcase activity across its autoimmune pipeline, though the Sjögren’s findings are from Phase 2. Article: Nipocalimab Phase 2 Sjögren’s disease data
Negative Sentiment: One report said ETFs were net sellers of J&J shares on Nov. 5, with net sales of $68.4 million. This is a potential technical headwind, but it reflects an earlier trading session and does not establish the reason for the current move. Article: ETFs Are Net Sellers of Johnson & Johnson

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. Royal Bank Of Canada dropped their target price on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Get Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

The stock has a market capitalization of $678.53 billion, a P/E ratio of 42.71, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The stock has a 50-day simple moving average of $265.91 and a 200 day simple moving average of $248.30.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently bought and sold shares of JNJ. Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG increased its position in shares of Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after buying an additional 1,225,676 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Johnson & Johnson by 11.5% in the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after buying an additional 1,530,070 shares in the last quarter. Amundi raised its stake in Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after buying an additional 2,001,139 shares during the period. Finally, Jupiter Topco LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth $1,967,399,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.